First small cohort (HCW) of sinovac (up to 18 Nov) >> interim analysis from Turkey (by Prof Serhat Unal) Sinovac = 3/752 = 0.4% (1 mild, 2 asymptomatic) Placebo=26/570= 4.56% (6 severe) There is no major safety issue Vaccine efficacy= 91.25% (71.3-97.3)

Bir klinisyen/istatistikçi gözüyle NNT ile ilgili problemler…. NNT (Number needed to treat) = Bir sonlanımı engellemek için tedavi edilmesi gereken hasta sayısı. x.com/veyselozgurbar…

We look forward to hearing your presentation ! (I.H.Tanboga, MD, PhD ) Lies, Damned Lies, Statistics and Researchers in COVID-19 era

29 Ocak Cuma, 19:00-21:00 saatleri arasında değerli hocamız Mithat Gönen 'in katılımıyla regresyon/randomizasyon konularını tartışacağız. İlgi duyan tüm arkadaşları bekleriz! Dijital Sağlık ve Biyoinformatik Derneği Arzu Kalayci MD MMSc Ilker Tekkesin, MD Mustafa Kiliçkap

full program zoom link bit.ly/3o8Molg

Our clinical prediction model (CORONATION) published in J of Med Virol. We included over 60.000 hospitalized pts w/ COVID-19. onlinelibrary.wiley.com/doi/pdf/10.100… 1/

Number of death/ICU and total no. pts according to EuroStat geographic NUTS 2/

We developed and validated our model according to the TRIPOD guidelines. We used both internal and internal-external (temporal and geographic) validations and also used "leave-one-EurostatsNUTS" internal-external cross-validation 3/

Here are multivariable association b/w continuous predictors and death 4/

Distribution of CORONATION risk score 5/

KM survival estimate according to CORONATION score deciles 6/

Calibration plot 7/

The nomogram of CORONATION score 8/

60.000 covid 19 hastası ile yapılan hastane içi mortaliteyi öngörme için geliştirilen skorlamayı içeren makalesi kabul olan I.H.Tanboga, MD, PhD hocamı ve çalışmaya katkı sunan değerli hocalarımızı tebrik ediyorum. Gürkan İmre Doç. Dr. Remzi SARIKAYA Dr. E.T. Erhan Tenekecioğlu Mehmet Birhan YILMAZ 🇹🇷

Let's RETWEET & submit questions to Edip Gurol - Topics: 1) Atrial Fibrillation detection 2) Left Atrial Appendage Closure 3) PFO Closure 4) New drugs/indications 5) NeuroCardiology syndromes. Cc C. Michael Gibson MD Dr. Deepak L. Bhatt Mohamad Alkhouli Luciano Sposato 🇦🇷🇨🇦 Shadi Yaghi Jan Scheitz 🧠⚡️❤️ Debbe McCall

Save the date!!! #brainheart Taylan Akgün Göksel Çinier @drerkanbaysal Bernas ALTINTAŞ Özcan Özeke Tolga Aksu, MD

Join me to congratulate I.H.Tanboga, MD, PhD for his new position as an asistant professor in biostatistics. Btw what is the P value 😂. Ben Van Calster Maarten van Smeden Can Yucel Karabay Ilker Tekkesin, MD Taylan Akgün Mert İlker Hayıroğlu @drerkanbaysal

Thank you very much Goksel🙏. Btw What I know about the p-value is that I actually don't know anything it😂😂😂

We can't say "ARNI didn't reduce primary outcome". Decreasing the hazard of primary outcome by a factor of 0.78 is clinically relevant! If they set their primary outcome as "time-to-first and recurrent" instead of time-to-first, results would be more clinically relevant

Cardiac troponins may have a prognostic role for risk stratification in COVID-19 I.H.Tanboga, MD, PhD European Atherosclerosis Society Atherosclerosis @ELS_Cardiology atherosclerosis-journal.com/article/S0021-…